AHF: Advocates Slam Gilead over Drug Profiteering

Protest Wednesday, June 21st, will target drug company CEO at company’s Foster City HQ

On Wednesday, June 21st, advocates and mobilizers affiliated with AIDS Healthcare Foundation (AHF) will host a protest targeting HIV and Hepatitis C drug giant Gilead Sciences over the Bay Area company’s drug pricing and policies. The protest will take place in front of Gilead’s headquarters in Foster City, CA. The action is part of a yearlong aggressive advocacy campaign by AHF hammering Gilead and Daniel O’Day, its multimillionaire CEO, over his and the company’s drug profiteering.

AHF Onsite Foster City Media Contact: Jesse Brooks, +1.510.575.8245 cell jesse.brooks@ahf.org

According to CEO World Magazine, Daniel O’Day, Chairman and CEO of Gilead Sciences, was the 4^th highest paid CEO in the healthcare industry in 2022 with total compensation of $21,621,253.

Advocates are protesting Gilead’s tone-deaf greed, particularly illegal restrictions the company placed early last year on access to 340B drug pricing for its branded hepatitis C treatments for certain pharmacies. Gilead now is one of more than 15 major drug companies that illegally have placed such restrictions on drugs.

AIDS Healthcare Foundation (AHF), the largest global AIDS organization, currently provides medical care and/or services to over 1.7 million individuals in 45 countries worldwide in the US, Africa, Latin America/Caribbean, the Asia/Pacific Region, and Eastern Europe. To learn more about AHF, please visit our website: www.aidshealth.org, find us on Facebook: www.facebook.com/aidshealth, follow us @aidshealthcare or subscribe to our AHF podcast “AHFter Hours.”

View source version on businesswire.com: https://www.businesswire.com/news/home/20230620528419/en/

The protest is part of a yearlong AHF campaign hammering Gilead & CEO Daniel O’Day, over his & the company’s drug profiteering, and esp. over illegal restrictions Gilead put on access to 340B Rx pricing for its Hep C treatments for some pharmacies.